Anavex Life Sciences has announced promising results from its latest phase 2b/3 study of blarcamesine, an investigational therapy targeting early Alzheimer’s disease. The clinical trial demonstrated significant reductions in amyloid-ß biomarkers, indicating the potential of blarcamesine to alter the course of neurodegeneration in Alzheimer’s patients. Spanning multiple centers across […]